Poehling Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Poehling Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$342K	Sell	2,677 -37	-1%	-$4.62K	0.07%	122
2025 Q4	$331K	Sell	2,714 -11	-0.4%	-$1.26K	0.07%	114
2025 Q3	$273K	Sell	2,725 -3	-0.1%	-$270	0.06%	122
2025 Q2	$226K	Sell	2,728 -5	-0.2%	-$399	0.05%	125
2025 Q1	$222K	Sell	2,733 -96	-3%	-$8.58K	0.06%	125
2024 Q4	$255K	Buy	2,829 +69	+3%	+$6.68K	0.06%	123
2024 Q3	$273K	Sell	2,760 -215	-7%	-$21.1K	0.07%	118
2024 Q2	$276K	Sell	2,975 -6	-0.2%	-$538	0.08%	119
2024 Q1	$283K	Sell	2,981 -15	-0.5%	-$1.39K	0.08%	112
2023 Q4	$268K	Sell	2,996 -10	-0.3%	-$743	0.08%	109
2023 Q3	$219K	Sell	3,006 -62	-2%	-$4.95K	0.08%	113
2023 Q2	$255K	Hold	3,068	–	–	0.09%	109
2023 Q1	$234K	Sell	3,068 -2	-0.1%	-$166	0.08%	108
2022 Q4	$255K	Sell	3,070 -502	-14%	-$40.6K	0.1%	103
2022 Q3	$283K	Sell	3,572 -8	-0.2%	-$674	0.12%	88
2022 Q2	$266K	Sell	3,580 -6,559	-65%	-$492K	0.1%	100
2022 Q1	$911K	Buy	10,139 +5,438	+116%	+$502K	0.28%	77
2021 Q4	$526K	Buy	+4,701	New	+$567K	0.17%	88
2018 Q3	–	Sell	-75	Closed	-$7K	–	263
2018 Q2	$7K	Hold	75	–	–	0.01%	246
2018 Q1	$7K	Hold	75	–	–	0.01%	255
2017 Q4	$6K	Buy	+75	New	+$6.28K	0.01%	233

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Poehling Capital Management's XBI Position: Q1 2026 in Review

Poehling Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.4% in Q1 2026, selling an estimated $4.62K and leaving 2,677 shares worth $342K. The position accounts for 0.07% of the portfolio, ranked #122.

Poehling Capital Management first reported a position in XBI in Q4 2017 and has held it in 21 quarters since. The position peaked at $911K in Q1 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Poehling Capital Management held 2,677 shares of State Street SPDR S&P Biotech ETF worth $342K as of Q1 2026.
Poehling Capital Management sold 37 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $4.62K.
State Street SPDR S&P Biotech ETF made up 0.07% of Poehling Capital Management's portfolio in Q1 2026, its #122 holding.
Poehling Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 21 quarters since.
Poehling Capital Management's State Street SPDR S&P Biotech ETF position peaked at $911K in Q1 2022.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Poehling Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.